Articles On Race Oncology (ASX:RAC)

The S&P/ASX 200 Index (ASX: XJO) is having another red day on Friday. In afternoon trade, the benchmark index is down 0.3% to 6,947.6 points. Four ASX shares that are falling more than most today are listed below. Here’s why they ar...

The share price of All Ordinaries Index (ASX: XAO) healthcare company Race Oncology Ltd (ASX: RAC) is having a day to forget after exiting a trading halt with the news of a leadership shakeup. The company’s executive director and chief...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

The Block Inc (ASX: SQ2) share price is on course to end the week on a very disappointing note. In morning trade, the payments company’s shares are down 15.5% to $91.99. Why is the Block share price crashing? Investors have been selling...

The ASX is expected to open lower once again on Friday after the Bank of England followed in the US Federal Reserve’s footsteps and raised UK interest rates on Thursday. The Bank of England hiked rates by 0.25 percentage points to 4.25 p...

Benchmark skips happily to an 0.87% rise for the day. Energy stacks on 4.5% while the techies recover from an early slump. Goldies the big losers as investors bail on safe havens because they just can’t help themselves.   The market opene...

Benchmark skips happily to an 0.87% rise for the day. Energy stacks on 4.5% while the techies recover from an early slump. Goldies the big losers as investors bail on safe havens because they just can’t help themselves.   The market opene...

The S&P/ASX 300 index may be trading notably lower than its recent highs, but that hasn’t stopped a couple of shares on the index from climbing to record highs today. The two ASX 300 shares that have reached these milestones are list...

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is racing higher again on Wednesday. In morning trade, the biotech company’s shares are up a further 14% to a multi-year high of $11.36. This means the ASX 300 share has now risen a w...

The S&P/ASX 200 Index (ASX: XJO) is out of form again on Tuesday. In afternoon trade, the benchmark index is down 1.65% to 6,992.1 points. Four ASX shares that are not letting that hold them back today are listed below. Here’s why th...

Well, it’s another day, another fall for the S&P/ASX 200 Index (ASX: XJO) so far this Tuesday. And not just any fall. At the time of writing, the Index has cratered by a depressing 2%, which drags the ASX 200 back below 7,000 points fo...

It’s been a fairly awful start to the week for ASX shares and the S&P/ASX 200 Index (ASX: XJO) so far today. This Monday has seen the ASX 200 take a significant hit, with investors shaken by what’s happening over on the US markets at t...

Race Oncology (RAC) executes a number of contracts to begin an observational cardioprotection breast cancer trial for its Zantrene product RCE appointed contract research organisations Resolutum Global, Beyond Drug Development, and NSW R...

The S&P/ASX 200 Index (ASX: XJO) has started the week in a subdued fashion. At the time of writing, the benchmark index is off its lows but down 0.2% to 7,130.1 points. Four ASX shares that are not letting that hold them back today ar...

Overall, it’s been a pretty negative day for the S&P/ASX 200 Index (ASX: XJO) and ASX shares so far this Monday. At the time of writing, the ASX 200 has lost around 0.46% of its value. Investors have probably been a little shocked by w...

Neuren Pharma gets a ‘historic’ FDA approval for DAYBUE to treat Rett syndrome Genetic Technologies published another research paper HITIQ sells 200 Nexus Head Impact Sensors to Monash University   Neuren Pharmaceuticals (ASX:NEU) surged...

Race Oncology (RAC) launches a new collaborative research project to uncover how its Zantrene product protects the heart from chemotherapy-induced damage The company has teamed up with the University of North Carolina in the US for the p...

It’s an exciting time for Race Oncology investors as the company appoints a new CEO and presses forward on multiple programs. Race Oncology (ASX:RAC) is making headway in exploring lead drug Zantrene as a potential therapy candidate to trea...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Race Oncology (RAC) receives human ethics approval for the next stage of its clinical trial of Zantrene in breast cancer patients The company received the approval from the Hunter New England Human Research Ethics Committee for the obser...

ASX investors love to see the insiders of companies they have shares in putting their money where their mouths are and buying shares of the businesses they are running. After all, the ultimate job of a company insider is to lead their comp...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

When a company director buys up 25,000 of their own company’s shares, it’s certainly an event to take note of. Yes, that’s what has happened this week with one ASX All Ords share.  Race Oncology Ltd (ASX: RAC) is an All Ords healthcare sh...

Race Oncology has announced the appointment of Damian Clarke-Bruce as its managing director and CEO.

Race Oncology (RAC) appoints Damian Clarke-Bruce as Managing Director and Chief Executive Officer, effective from February 1, 2023The role comes with a $475,000 yearly salary and a short-term incentive of up to 40 per cent of this base sala...

Clarity Pharma announced positive results from Phase 1 trial Starpharma brings VIRALEZE to Indonesia Race Oncology has a new CEO   Clarity Pharma (ASX:CU6) announced that its diagnostic 64Cu SAR-bisPSMA Phase I trial PROPELLER has met all...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

Race Oncology received positive feedback from the US FDA HeraMed launches HeraCARE in Victoria Mesoblast announced top line results from Phase 3 trial   US FDA pleased with Race Oncology submission Race Oncology (ASX:RAC) has received pos...

It’s quarterlies season as the ASX market announcements page becomes increasingly flooded with lodgements. Pandemic recovery stocks like CTD and sports betting tech Blubet shone, while COVID play JB Hi-Fi continues to show growth. Here’s so...

We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month   There were 191 ASX IPOs in...

It’s Tuesday afternoon, and after a long, hard day buying and selling bits of paper that say you own small portions of much larger things, you owe it to yourself to sit back and relax in front of a warm, crackling fire. So crack open a bott...

Daniel Tillet of Race Oncology (RAC) speaks at the Switzer Small and Micro Cap Investor Strategy Day September 2022.

Special Report: A new breakthrough formulation for Race Oncology’s lead asset drug Zantrene means it has significantly increased its potential market. Race Oncology (ASX:RAC) is poised to increase its addressable market significantly after...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

Healthcare is one of those industries that enjoys relatively stable demand through tougher economic times. With consecutive interest rises forcing Australians to close their wallets, this might be a consideration for the coming period. But...

Whitehaven Coal Ltd (ASX: WHC) shares are having a roller coaster day today. The coal producer’s shares are rising 5.58% and are currently trading for $9.65. For perspective, the S&P/ASX 200 Index (ASX: XJO) is rising 3.64% today. L...

There’s no getting away from the fact that it has been a difficult year for investors. Since the start of the year, the S&P/ASX 200 Index (ASX: XJO) has lost almost 15% of its value. This means that if you had invested $1,000 at the sta...

The Cogstate Limited (ASX: CGS) share price has continued its ascent on Thursday. In morning trade, the neuroscience technology company’s shares are up a further 17% to $2.24. Though, it is worth noting that the Cogstate share price was up...

After a promising start to Wednesday’s trade, the S&P/ASX 200 Index (ASX: XJO) handed back its gains to slump lower. The index closed 0.53% lower at 6,462 points. It followed another rough session on Wall Street. After falling into a b...

Wednesday morning saw healthcare stock Race Oncology [ASX:RAC], developer of cancer drug treatments and melanoma therapies, provide an update on an improved formulation of its Zantrene (RC220) product. The post Race Oncology Shares Go Up On...

The S&P/ASX 200 Index (ASX: XJO) has resumed its downward trend on Wednesday. In afternoon trade, the benchmark index is down 0.8% to 6,442.4 points. Four ASX shares that are not letting that hold them back today are listed below. Here...

The Whitehaven Coal Ltd (ASX: WHC) share price has been a big performer for shareholders in 2022. Whitehaven shares have risen by 225% in the year to date. It’s up by another 5% today. This year the business has benefited from the rising c...

ASX coal shares opened strongly on Wednesday, with the share prices of the biggest players surging. The New Hope Corporation Limited (ASX: NHC) share price is up 6.3% to $6.09 at the time of writing. Whitehaven Coal Ltd (ASX: WHC) shares...

Race Oncology (RAC) develops a new and improved formulation of its Zantrene product that enables peripheral intravenous (IV) delivery, expanding its potential marketThe company says peripheral IV administration can provide a better quality...

Benchmark rises early, wobbles late, gains 0.4% Small caps all over the shop today, up 0.9% Metals Grove jumps over 50%    Local markets have climbed the mountain of conflict today: (NB: explicit language).   The ASX 200 index was initia...

PYC Therapeutics and Race Oncology announce new RNA programs Recce Pharma accelerates its clinical programs Orthocell gets first purchase orders The race is hotting up to develop the next RNA-based drug discovery, as a couple of ASX liste...

Monday was not the start to the week that investors were probably hoping for. By the time the closing bell belted out its chime, the S&P/ASX All Ords Index (ASX: XAO) had taken a 2% beating to the downside. Not even the release of ear...

Race Oncology’s lead asset drug Zantrene has shown that it is effective in reducing the risk of heart damage for patients undergoing standard of care chemotherapy. It’s well known for decades that chemotherapy is highly effective in destro...

Race Oncology (RAC) advanced studies of its cancer-treating drug, Zantrene over the June quarter The drug was found to protect the hearts of mice against the damage caused by certain chemotherapy drugs During the period, the company report...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...